Low-dose corticosteroids. Our study suggests that there was no benefit of high-dose corticosteroids devoid of tocilizumab compared with low-dose corticosteroids with tocilizumab but there’s signal that each can improve outcomes over low-dose corticosteroids alone. Our findings are compatible with current NIH therapy recommendations for patients with COVID-19 ARDS requiring mechanical ventilation, which suggest dexamethasone 6 mg per day (low dose) for 10 days plus tocilizumab. Future potential research are necessary to determine the optimal dose of corticosteroids within this patient population. Declaration of Conflicting InterestsThe authors declared no possible conflicts of interest with respect to the analysis, authorship, and/or publication of this article.Pevonedistat Katz et al FundingThe authors received no monetary assistance for the research, authorship, and/or publication of this short article.Iniparib 11. Salama C, Han J, Yau L, et al. Tocilizumab in individuals hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;384(1):20-30. doi:ten.1056/NEJMoa2030340. 12. Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40(1):38-49. doi:ten.1016/j.recommendations.2018.11.002. 13. Ahmed MH, Hassan A. Dexamethasone for the remedy of coronavirus illness (COVID-19): a review. SN Compr Clin Med. 2020;2:1-10. doi:10.1007/s42399-020-00610-8. 14. Liu QQ, Cheng A, Wang Y, et al. Cytokines and their partnership with all the severity and prognosis of coronavirus illness 2019 (COVID-19): a retrospective cohort study. BMJ Open. 2020;10(11):e041471.PMID:25959043 doi:10.1136/bmjopen-2020-041471. 15. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525533. doi:ten.1038/ncprheum0898. 16. Planet Wellness Organization. Tracking SARS-CoV-2 variants. Accessed March 18, 2022. https://www.who.int/en/activities/ tracking-SARS-CoV-2-variants/. 17. Polak SB, Van Gool IC, Cohen D, von der Thusen JH, van Paassen J. A systematic assessment of pathological findings in COVID-19: a pathophysiological timeline and probable mechanisms of illness progression. Mod Pathol. 2020;33(11):2128-2138. doi:ten.1038/s41379-020-0603-3. 18. Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):21562168. doi:10.1038/s41379-020-00661-1. 19. Sterne JAC, Murthy S, Diaz JV, et al. Association among administration of systemic corticosteroids and mortality amongst critically ill patients with COVID-19 a meta-analysis. JAMA. 2020; 324(13):1330-1341. doi:10.1001/jama.2020.17023. 20. Li S, Hu Z, Song X. High-dose but not low-dose corticosteroids potentially delay viral shedding of sufferers with COVID-19. Clin Infect Dis. 2021;72(7):1297-1298. doi:ten.1093/cid/ciaa829. 21. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill individuals with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(six):757767. doi:ten.1164/rccm.201706-1172OC. 22. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid therapy on plasma SARS-associated Coronavirus RNA concentrations in adult individuals. J Clin Virol. 2004;31(4):304-309. doi:ten.1016/j.jcv.2004.07.006. 23. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492-500. doi:ten.1086/600383. 24. Li X, Xu.